Jim Cramer Questions Pfizer's Growth Prospects: "I Can't Find the Growth"
On Mad Money, Jim Cramer expressed skepticism about Pfizer's (PFE) growth prospects, pointing to earnings growth problems and the Seagen acquisition not working as expected. He noted the 7% dividend remains safe.
Key Numbers
According to Insider Monkey, during a segment of Mad Money, financial commentator Jim Cramer shared his views on Pfizer Inc. (NYSE:PFE) in response to a caller's question. Cramer said: "Okay, they do have earnings growth problems. They haven't been able to make the Seagen acquisition work the way it should. The dividend is safe at 7%."
Rating Change
Cramer did not issue an explicit buy or sell recommendation, but his comments reflect a negative view on growth prospects. The stock currently trades at a high dividend yield, which may attract income investors.
Analyst's Rationale
Cramer focuses on two key points:
- Earnings growth problems: Pfizer faces challenges in achieving earnings growth after the decline in COVID-19 vaccine revenue.
- Seagen acquisition struggles: The $43 billion deal has not yet delivered the expected synergies.
Context
Cramer's comments come as Pfizer faces pressure to offset the decline in COVID product revenues. Many analysts see the high dividend yield (7%) as support for the stock, but future growth depends on the success of its pipeline and acquisitions.
What to Make of It
Cramer's remarks highlight Pfizer's challenges in the post-COVID era. While the dividend remains attractive, long-term growth is uncertain. Investors should monitor the progress of the Seagen acquisition and pipeline performance.
Frequently Asked Questions
Found this useful? Share it